Evidence map›Paper›PMID 40580268›Full record

ArticleJournal of prevention (2022)2025

Commentary - Community Involvement and Prevention Science in and with Communities - Where do we go next?

Jeremy Segrott, Ina Koning, Boris Chapoton

Abstract read
In one paragraph

Article in Journal of prevention (2022), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jeremy SegrottCentre for Trials Research, DECIPHer Centre, Cardiff University, Wales, UK. segrottj@cardiff.ac.uk.ORCID http://orcid.org/0000-0001-6215-0870
Ina KoningClinical Child and Family Studies, Vrije Universiteit, Amsterdam, Netherlands.ORCID http://orcid.org/0000-0003-0305-0487
Boris ChapotonUniversité Jean Monnet, Saint-Etienne, CoActiS UR4161, France.ORCID http://orcid.org/0000-0001-9199-5821

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This commentary piece reflects on the 2024 EUSPR Conference and its theme of ‘Prevention in and with communities’. We discuss the challenges that Prevention Science needs to address as it develops community involvement in its work. After briefly summarising some of the key definitions and boundaries of community involvement, we consider three key challenges which were highlighted during the Cremona conference. The first concerns the importance of building skills and capacity for community involvement and the role of organisations such as the EUSPR. Second, we explore the challenges of balancing involvement of the community and safeguarding evidence-based-practice principles (EBP), and potential strategies to achieve this. Community involvement need not be in opposition to research evidence or the principles of EBP. Third, the value of assessing the impact and quality of community involvement is discussed. We look at the need for researchers to report on the design and outcomes of community involvement, and the imperative to avoid causing harm such as excluding certain individuals/groups. In the concluding section of the commentary, we answer the question of ‘Where do we go next?’ by highlighting some specific steps in which the EUSPR (and other Prevention Science societies) have an important contribution to make. These include training and capacity building, knowledge exchange on the implementation of community involvement within research projects and developing dialogues with the public whose communities the EUSPR conference takes place within.

Indexed as

Community ParticipationEvidence-Based PracticeHumansCommunitiesCommunity involvementParticipatory researchPrevention SciencePublic involvement

Identifiers

PMID40580268
PMCPMC12553557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.